The bill, which faced significant pushback from drugmakers, industry lobby groups and patient advocacy groups, would require drugmakers to inform state officials and insurers of insulin price increases 90 days in advance. Drugmakers would also be required to publicly share annual list prices and profits for insulin, along with other currently private information.
Groups in opposition to the bill said the legislation did not account for rebates paid to middlemen and unfairly targets diabetes patients.
Mr. Sandoval said the bill contained well-intentioned provisions to increase access to affordable healthcare, but also carried potentially harmful consequences for state residents, including “the possibility that access to critical care will become more expensive, more restricted and less equitable,” reports Las Vegas Review Journal.
More articles on supply chain:
Premier: 9 policy recommendations to fix high drug costs
6 FDA decisions to keep an eye on in June
Eli Lilly CFO to retire at year-end
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
